to test the efficacy of inhaled pulmonary surfactant replacement therapy in adults with COVID-19 disease | Pandemic PACT Tracker

Key facts

Disease
COVID-19
start year
2020
Known Financial Commitments (USD)
$1,648,270
Funder
Gates Foundation
Principal Investigator
.
Research Location
United Kingdom
Lead Research Institution
The University of Southampton
Research Priority Alignment
N/A

Research Category
Clinical characterisation and management
Research Subcategory
Supportive care, processes of care and management
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified

Abstract

Publicationslinked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

A randomized controlled trial of nebulized surfactant for the treatment of severe COVID-19 in adults (COVSurf trial).

Surfactant Proteins SP-B and SP-C in Pulmonary Surfactant Monolayers: Physical Properties Controlled by Specific Protein-Lipid Interactions.

Identification of a New Cholesterol-Binding Site within the IFN-γ Receptor that is Required for Signal Transduction.

Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.